Ken Griffin Aim Immuno Tech Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 48,655 shares of AIM stock, worth $3,892. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,655
Previous 358,987
86.45%
Holding current value
$3,892
Previous $71,000
92.96%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AIM
# of Institutions
37Shares Held
4.83MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA2.44MShares$195,5450.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$55,8610.0% of portfolio
-
Geode Capital Management, LLC Boston, MA531KShares$42,5060.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny318KShares$25,4380.0% of portfolio
-
State Street Corp Boston, MA173KShares$13,8480.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $3.84M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...